Clinical Trial Update: Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating the efficacy, safety and immunogenicity of a Recombinant Zoster Vaccine (CHO Cell) in adults age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Recombinant Zoster Vaccine (CHO Cell) (recombinant zoster vaccine (CHO cell))

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Herpes Zoster | Phase 3 | Status: ACTIVE_NOT_RECRUITING